Gevorg Tamamyan: Waiting to see promising bot/bal results from our lung cancer trial
Gevorg Tamamyan posted on LinkedIn:
“Just saw the presentation from ESMO GI Annual Congress and the outstanding results after neoadjuvant botensilimab and balstilimab in colorectal cancer. The images are from a 40-year-old female with Stage 3 MSS Colorectal Cancer (CRC), after 7 weeks with BOT/BAL therapy – complete response (100% tumor reduction)! Congratulations to all the great team of investigators – Pashtoon Kasi and colleagues and of course, wonderful Agenus team!
Waiting for similar results also from our lung cancer trial with BOT/BAL (NCT06322108), conducted by our Immune Oncology Research Institute.
We need to hurry up, because cancer and patients cannot wait!”
Source: Gevorg Tamamyan/LinkedIn
Gevorg Tamamyan is the Editor-in-chief of OncoDaily, President-Elect of SIOP Asia Continental Branch and Pediatric Oncology East and Mediterranean (POEM) Group, and the CEO of the Immune Oncology Research Institute (IMMONC).
He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023